Erin Harris
Click here to email Erin.
Erin Harris is chief editor of Cell & Gene and a contributing editor to Life Science Leader magazine. She studied English and psychology at Lafayette College and has 20+ years of experience in B2B publishing. Erin spent 10 years covering and reporting on the adoption of information technology from a B2B perspective. She’s written on technology topics ranging from Big Data and analytics to security and e-commerce. In each case, her reporting centered on innovations that improved operational efficiencies, fostered interdepartmental collaboration, or enhanced supply chains. Currently, she writes actionable information for professionals involved in the development and commercialization of cell and gene therapies. She covers the entire product lifecycle from basic research to commercialization. Erin has interviewed executives from Fortune 500 as well as startups. She has moderated panel discussions and has spoken at numerous industry events from large conferences to niche forums.
ARTICLES BY ERIN HARRIS
-
![Aman Khera, Global Head of Regulatory Strategy at Worldwide Clinical Trials]( "Diversity And Inclusion In The Cell And Gene Sector")
Diversity And Inclusion In The Cell And Gene SectorAman Khera, Global Head of Regulatory Strategy at Worldwide Clinical Trials answers my questions about the state of diversity and inclusion specifically in the cell and gene sector.
-
![Cell Gene]( "Inside Sangamo’s Decision to Build an In-House AAV Manufacturing Facility")
Inside Sangamo’s Decision to Build an In-House AAV Manufacturing FacilityAndy Ramelmeier, EVP Technical Operations at Sangamo Therapeutics and I sat down to discuss Sangamo’s plans for its in-house AAV manufacturing facility and the major benefits the facility will bring to genomic medicine and the sector at large.
-
![iStock-1087218874]( "Expression Therapeutics’ In-House Manufacturing Model — How And Why")
Expression Therapeutics’ In-House Manufacturing Model — How And WhyExpression Therapeutics is building its own clean room. Here's why.
-
![iStock-528181173]( "The Case For In-House Manufacturing Of Cell Therapies")
The Case For In-House Manufacturing Of Cell TherapiesPartnering with CMOS and CDMOs does not always make the most cost-effective sense especially when speed to clinical trial is most important.
-
![Diversity photo grid_450x300.jpg]( "Driving Diversity And Inclusion In Life Sciences")
Driving Diversity And Inclusion In Life SciencesExperts weigh in on actionable ways to develop, implement, and require a diverse and inclusive working environment that drives innovation and profitability in life sciences.
-
![Recap]( "Dr. Levine’s ISCT 2020 Recap")
Dr. Levine’s ISCT 2020 RecapI caught up with Dr. Levine on the recent ISCT 2020 meeting as well as the first-in-U.S. CRISPR-edited immune cells.
-
![Philadelphia Skyline]( "Philadelphia As A Cell & Gene Therapy Hub")
Philadelphia As A Cell & Gene Therapy HubSaul Behar, Senior Vice President, Advancement and Strategic Initiatives at University City Science Center explains why Philadelphia has a unique combination of factors in terms of the strength of its assets around academic institutions, healthcare institutions, and its rich pharma legacy
-
![Research and development R&D]( "The Greater Philadelphia Region As R&D, Manufacturing Hubs")
The Greater Philadelphia Region As R&D, Manufacturing HubsCell & Gene’s Chief Editor Erin Harris asks Claire Marrazzo Greenwood, Executive Director, CEO Council for Growth & VP, Leadership Engagement at Chamber of Commerce for Greater Philadelphia about the Greater Philadelphia region as an R&D, commercialization, and manufacturing hub.
-
![Research Study]( "Inside The Cell And Gene Therapy And Connected Health Workforce Analysis")
Inside The Cell And Gene Therapy And Connected Health Workforce AnalysisJust recently, an independent study to analyze the current workforce landscape and assess the future talent needs of the Greater Philadelphia region’s cell and gene therapy and connected health sectors has found that this workforce is expected to grow between 35 percent to 94 percent in the next 10 years using mid-range growth estimates. The growth could be as much as 54 percent to 136 percent using high-range growth estimates.
-
![Blue cells 450x300]( "Inside Protalix BioTherapeutics’ Phase 3 BRIDGE Study")
Inside Protalix BioTherapeutics’ Phase 3 BRIDGE StudyProtalix BioTherapeutics the significance of the positive topline results from the Phase III BRIDGE open-label switch-over study.
